The Latin America, Middle East and Africa Spinal Muscular Atrophy Treatment Market should witness market growth of 23.3% CAGR during the forecast period (2022-2028).
To diagnose, many doctors take the blood sample of patients to check for broken or missing genes that might be responsible for SMA. Additionally, doctors can also diagnose the levels of creatine kinase (CK) enzyme that leaches out of muscles. Certain other tests can also be prescribed to ascertain the condition of SMA.
These include nerve tests (like electromyogram), computed tomography (CT), magnetic resonance imaging (MRI), as well as muscle tissue biopsy. Before the innovation of SMN replacement therapies that target genes, numerous methods have been considered to increase the levels of SMN by utilizing drugs that would target the SMN gene.
With the growing advancement in the availability of SMA treatments, this method might not be used as much, but it is still a vital method as a therapy to enhance the SMN expression in the patient. The growing incidences of SMA and the increasing approval rate of SMA-oriented gene therapy are propelling the demand for SMA treatments further.
Patients in Latin America who suffer from hereditary neuromuscular diseases (NMDs) frequently lack access to specialist medical facilities, and many of them go untreated. Due to the region's diverse healthcare system, there are differences in the general administration and care of patients with spinal muscular atrophy (SMA). Both in the public and private sectors, a dynamic new generation of clinical neurologists is being educated for the specialized treatment of SMA as well as other neuromuscular (NM) patients.
The Brazil market dominated the LAMEA Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $131.2 million by 2028. The Argentina market is experiencing a CAGR of 23.9% during (2022-2028). Additionally, The UAE market would display a CAGR of 22.9% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
To diagnose, many doctors take the blood sample of patients to check for broken or missing genes that might be responsible for SMA. Additionally, doctors can also diagnose the levels of creatine kinase (CK) enzyme that leaches out of muscles. Certain other tests can also be prescribed to ascertain the condition of SMA.
These include nerve tests (like electromyogram), computed tomography (CT), magnetic resonance imaging (MRI), as well as muscle tissue biopsy. Before the innovation of SMN replacement therapies that target genes, numerous methods have been considered to increase the levels of SMN by utilizing drugs that would target the SMN gene.
With the growing advancement in the availability of SMA treatments, this method might not be used as much, but it is still a vital method as a therapy to enhance the SMN expression in the patient. The growing incidences of SMA and the increasing approval rate of SMA-oriented gene therapy are propelling the demand for SMA treatments further.
Patients in Latin America who suffer from hereditary neuromuscular diseases (NMDs) frequently lack access to specialist medical facilities, and many of them go untreated. Due to the region's diverse healthcare system, there are differences in the general administration and care of patients with spinal muscular atrophy (SMA). Both in the public and private sectors, a dynamic new generation of clinical neurologists is being educated for the specialized treatment of SMA as well as other neuromuscular (NM) patients.
The Brazil market dominated the LAMEA Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $131.2 million by 2028. The Argentina market is experiencing a CAGR of 23.9% during (2022-2028). Additionally, The UAE market would display a CAGR of 22.9% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Scope of the Study
By Type
- Type 1
- Type 2
- Type 3
- Type 4
By Route of Administration
- Injection
- Oral
By Treatment Type
- Drug
- Spinraza
- Zolgensma (AVXS-101)
- Evrysdi
- Others
- Gene Therapy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F.Hoffmann-La Roche Ltd. (Genentech, Inc.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Spinal Muscular Atrophy Treatment Market by Type
Chapter 5. LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration
Chapter 6. LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type
Chapter 7. LAMEA Spinal Muscular Atrophy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Methodology
LOADING...
